X Close
TMCnet - World's Largest Communications and Technology Community



Interleukin Genetics Publishes Additional Evidence for the PerioPredict™ Genetic Risk Test in Journal of Periodontal Research
[April 11, 2014]

Interleukin Genetics Publishes Additional Evidence for the PerioPredict™ Genetic Risk Test in Journal of Periodontal Research

WALTHAM, Mass. --(Business Wire)--

Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the pre-print online publication of its research study titled "Association of interleukin-1 gene variations with moderate to severe chronic periodontitis in multiple ethnicities" in the Journal of Periodontal Research. The study results from multiple ethnic groups further validated the association between periodontitis and the interleukin-1 beta (IL1B) composite genotype pattern, a specific genetic profile that can be elucidated by Interleukin's PerioPredictTM genetic risk test. In addition, the study results demonstrated that detection of the IL1B variations tested provided added value in the prediction of moderate to severe periodontitis above and beyond the risk attributable to smoking and diabetes alone.

PerioPredict™ measures variations in genes for interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. This international study, which included over 1,500 individuals, aimed to test the hypothesis that the utilization of functional IL-1 gene variations would allow the test to be valuable across multiple ethnic groups. In the discovery phase of the project which tested Caucasians and African Americans, the study results showed that there was significant association between the presence of IL1B single nucleotide polymorphisms and moderate to severe periodontitis. This association was further confirmed in two additional studies consisting of Hispanics and Asians and in a meta-analysis of all three populations. The study validates the influence of IL-1 genetic factors on the development of moderate to severe periodontitis.

"This study expands our evidence into additional ethnic populations and demonstrates that our test can be utilized accurately, in dental offices, regardless of ethnicity, and adds value to standard risk factors for more severe periodontitis," said Dr. Kenneth Kornman, Chief Executive Officer of Interleukin Genetics. "The PerioPredict genetic test, together with smoking and diabetes, has previously been shown in a study of over 5,000 patients to be able to classify individuals who respond differently to preventive dental care."

The omplete publication can be accessed here: http://onlinelibrary.wiley.com/doi/10.1111/jre.12181/pdf

About Periodontitis

Periodontitis is a chronic inflammatory disease initiated by specific bacteria that activate host mechanisms destroying the bone and connective tissues that support the teeth. Between 8% and 13% of the worldwide adult population exhibit severe generalized periodontitis, with many more having clinical signs of moderate disease. Individuals who have a history of periodontitis and have been appropriately treated require more preventive care to maintain health. Current treatments to prevent gum disease are good oral hygiene and a recommended two dental cleanings per year, even though there is little evidence to support multiple routine cleanings. The previously published "Patient Stratification for Preventive Dental Care" study (Giannobile et al. 2013) suggests that individuals who are at higher risk for periodontal disease may benefit from 3-4 cleanings per year while those at lower risk may need only one cleaning per year. The Company believes risk stratification of patients without a history of periodontitis may optimize preventative dental care to improve outcomes and reduce long-term oral healthcare expenses.

About PerioPredict™

The PerioPredict™ genetic test is quick, easy and painless and is performed by dentists during a routine exam or cleaning. PerioPredict™ measures variations in genes for Interleukin-1 (IL-1), a key mediator of inflammation, and identifies individuals who are at increased risk for moderate to severe periodontal disease. The PerioPredict™ test results provide essential information to the dental professional for assessing prevention and treatment options for their patients. PerioPredict™ is run solely in the Interleukin Genetics CLIA-certified lab in Waltham, MA.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic diseases and health related conditions. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PerioPredict™ genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA). For more information please visit www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Company's annual report on Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.

[ Back To TMCnet.com's Homepage ]

Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.


© 2015 Technology Marketing Corporation. All rights reserved | Privacy Policy